Arizona Patent of the Month – August 2024
Lysosomal storage diseases, including Niemann-Pick, Gaucher, and Fabry diseases, are some of the most challenging genetic disorders to manage due to their complex symptoms and severe impact on patients’ quality of life. These disorders arise from the abnormal accumulation of lipids like sphingomyelin in cells, leading to a range of symptoms from cognitive decline to systemic organ failure. Traditional treatments focus on symptom management rather than targeting the root cause of lipid accumulation. Enter Wylder Nation Foundation, which has pioneered an innovative method that may change the course of treatment for these debilitating diseases.
At the core of this breakthrough is the use of Fatty Acid Amide Hydrolase inhibitors (FAAHi). This class of drugs helps address the lipid accumulation problem at its root by increasing levels of endocannabinoids, natural compounds in the body that interact with cannabinoid receptors to regulate physiological processes. Specifically, FAAHi can activate the CB1 cannabinoid receptor, known to play a crucial role in cellular homeostasis, especially in the brain and other critical organs. By activating this receptor, the treatment promotes the degradation of sphingomyelin, reducing its accumulation and thereby alleviating symptoms associated with lysosomal storage disorders.
This treatment offers a multifaceted approach. It aims not only to lower sphingomyelin levels but also to improve cognitive functions, motor skills, and overall health. For patients suffering from Acid Sphingomyelinase Deficiency (ASMD), Niemann-Pick disease types A, B, and C, and other related conditions, the implications are profound. This method could potentially extend lifespans and enhance the quality of life significantly, offering hope where there was little before.
FAAHi treatment is versatile, allowing for potential combination therapies. It can be administered alongside other agents like recombinant acid sphingomyelinase or even gene therapy, providing a comprehensive strategy to combat these diseases. With further research and clinical trials, Wylder Nation Foundation’s approach could mark a significant milestone in the treatment of lysosomal storage diseases, paving the way for new therapies that offer real relief for patients and families affected by these conditions.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
